Skip to main content

Table 1 Characteristic of studies included in the meta-analysis

From: Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials

Study Intervention Control No. of patient Gender (female) Mean age, y Co-morbidity of CVDs Co-morbidity of diabetes Total cholesterol (mmol/L) GFR (ml/min/1.73 m2) Creatinine (mg/dL) LDL lowing Follow-up (month) Jadad score
CARE(2003)34 Pravastatin Placebo 1711 369(21.6%) 64.3 AMI NR 5.40 NR 1.26 NR 58.9 3
HPS(2003)27† Simvastatin Vitamins/Placebo 1329 NR NR NR NR NR NR NR NR 57.0 2
PPP(2004)23 Pravastatin Placebo 16824 1840(10.9%) 59.5 NR NR 6.05 68.5 1.18 51.1% 60.0 3
PREVENDIT (2004)24 Pravastatin Fosinopril/Placebo 864 303(35.1%) 51.3 NR 3% 5.80 NR 1.02 24.4% 46.0 4
LIPIS(2005)31 Pravastatin Placebo 310 102(33%) 69.0 PCI NR 5.17 NR 1.33 NR 46.0 2
4S Study (2007)28 Simvastatin Placebo 2314 618(26.7%) 60.5 CHD NR 6.75 65.2 1.5 38.0% 65.5 2
ATIC(2007)25 Pravastatin Placebo 93 40(43.0%) 53.0 No history of AOD Excluded diabetes 5.60 33.5 2.32 26.1% 18.0 5
TNT(2008)30 Atorvastatin Atorvastatin 3107 1005(32.3%) 65.5 CHD NR 4.55 52.9 NR 18.0% 60.0 2
AFCAPS (2009) Lovastatin Placebo 304 65(21.4%) 62.0 No history of CVD Excluded diabetes 5.74 53.0 1.4 27.0% 64.0 3
ALLIANCE (2009)29 Atorvastatin Usual Care 579 134(23.1%) 65.2 CHD NR 5.89 51.2 1.5 34.5% 54.3 2
MEGA(2009)26 Pravastatin Diet 7196 NR NR No history of CVD NR NR 65.0 NR 18.5% 64.0 2
JUPITER (2010)33 Rosuvastatin Placebo 3267 2129(65.2%) 70.0 NR Excluded diabetes 4.89 56.0 NR 52.0% 22.8 2
SHARP (2011)14 Simvastatin Placebo 6247 NR NR No history of MI NR NR NR NR 68.0% 58.8 5
  1. Abbreviations: CVD cardiovascular disease, LDL low density lipoprotein, AMI acute myocardial infarction, PCI percutaneous coronary intervention, CHD coronary heart disease, AOD arterial occlusive disease, MI myocardial infarction, NR not reported, GFR Glomerular filtration rate. : only a subgroup of the total study was included.